NLRC3 enhances antitumor immunity by specifically negatively regulating M-MDSCs in a STING-dependent manner.
Enhancing NLRC3 protein narrows the immunosuppressive cell population in tumors and synergizes with existing immunotherapy in mouse models.
This mechanistic study demonstrates that NLRC3 reduces immunosuppressive M-MDSC infiltration in the tumor microenvironment through STING pathway inhibition, offering a new dual NLRC3/STING combination immunotherapy strategy. NLRC3 overexpression synergizes with the STING agonist cGAMP to suppress tumor growth in mouse models, suggesting NLRC3 as a novel immunotherapy target warranting future translational investigation.
What the study was
- Study design
- Mechanistic preclinical study (mouse tumor models and cell biology)
- Population
- Mouse syngeneic tumor models; M-MDSC mechanistic cell biology
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Cellular and Molecular Immunology
Why it surfaced
Novel NLRC3/STING/M-MDSC immunotherapy mechanism with antitumor efficacy in mouse models; Cellular & Molecular Immunology; preclinical only.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.